BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16888865)

  • 1. Diabetes basics. Exenatide and pramlintide. New meds on the block.
    Griffin S; Borders J
    Diabetes Self Manag; 2006; 23(4):74-6, 79. PubMed ID: 16888865
    [No Abstract]   [Full Text] [Related]  

  • 2. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide and pramlintide: new therapies for diabetes.
    Want LL; Ratner R
    Int J Clin Pract; 2006 Dec; 60(12):1522-3. PubMed ID: 17109659
    [No Abstract]   [Full Text] [Related]  

  • 4. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
    Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
    Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First in class. Two new diabetes drugs.
    Koredella T
    Diabetes Forecast; 2005 Aug; 58(8):35-6. PubMed ID: 16124101
    [No Abstract]   [Full Text] [Related]  

  • 7. Type 2 diabetes drug boom: is newer better?
    Johns Hopkins Med Lett Health After 50; 2007 Aug; 19(6):3, 7. PubMed ID: 17712909
    [No Abstract]   [Full Text] [Related]  

  • 8. Is pramlintide an adjunct to insulin therapy?
    Charles MA
    Diabetes Technol Ther; 2002; 4(2):190-2. PubMed ID: 12079622
    [No Abstract]   [Full Text] [Related]  

  • 9. New drugs: exenatide, pramlintide acetate, and micafungin sodium.
    Hussar DA
    J Am Pharm Assoc (2003); 2005; 45(4):524-7. PubMed ID: 16128511
    [No Abstract]   [Full Text] [Related]  

  • 10. Are you up-to-date on diabetes medications?
    Scemons D
    Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for diabetes: pramlintide and exenatide.
    Jones MC
    Am Fam Physician; 2007 Jun; 75(12):1831-5. PubMed ID: 17619527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
    J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC; Grasso P
    Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
    Ceriello A; Lush CW; Darsow T; Piconi L; Corgnali M; Nanayakkara N; Frias JP; Maggs D
    Diabetes Metab Res Rev; 2008 Feb; 24(2):103-8. PubMed ID: 17694505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of pramlintide, an analog of amylin, on the regulation of glycemia].
    Girard J
    Journ Annu Diabetol Hotel Dieu; 1998; ():315-20. PubMed ID: 9773629
    [No Abstract]   [Full Text] [Related]  

  • 19. Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.
    Odegard PS; Setter SM; Iltz JL
    Diabetes Educ; 2006; 32(5):693-712. PubMed ID: 16971704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.